FDA Okays First Generic Naloxone Nasal Spray for Opioid Overdose Print
Written by FHI's Week in Review   
Tuesday, 23 April 2019 10:18
Megan Brooks reports for Medscape on Apr. 19:
The U.S. Food and Drug Administration (FDA) has granted final approval for the first generic naloxone hydrochloride nasal spray (Narcan, Teva Pharmaceuticals) that can stop or reverse the effects of an opioid overdose. The FDA tentatively approved this generic drug product in June 2018. Teva's generic naloxone nasal spray is the first for use in the community setting by individuals who have no medical training. The name-brand spray was approved in 2015.
Read more in the current issue of Week in Review>>

Last Updated on Monday, 13 May 2019 18:29